Q32 Bio confirmed it has launched an underwritten public offering of common stock and, in certain cases, pre-funded warrants in lieu of common shares, seeking gross proceeds of $200 million. The company also plans to provide the underwriters a 30-day option to buy up to an additional $30 million of shares at the public offering price, less customary underwriting discounts and commissions.
The clinical-stage biotechnology firm said the net proceeds are intended for working capital, specifically naming expenses tied to research, clinical development and commercialization activities. The statement highlighted that some of the funding will be allocated to support the advancement of bempikibart into future clinical trials.
Underwriting responsibilities for the deal are being led by Morgan Stanley, Jefferies and Cantor as joint book-running managers. Oppenheimer & Co. is participating as a book-running manager, and H.C. Wainwright & Co. is serving as lead manager.
Market reaction was mixed. Shares of Q32 Bio fell approximately 6% in after-hours trading on Monday following the public offering announcement. Earlier in the regular session, the stock had jumped about 90% after the company released 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial, which is evaluating bempikibart - an anti-IL-7Ralpha antibody - in patients with severe or very severe alopecia areata.
Q32 Bio is a clinical-stage company focused on developing treatments for alopecia areata and other autoimmune and inflammatory diseases. The firm positioned the financing as a means to bolster its balance sheet to continue ongoing research and to support the planned progression of its lead candidate through additional clinical work.
Key details:
- Planned offering: $200 million in common stock and pre-funded warrants.
- Underwriter option: 30-day option to purchase up to an additional $30 million of shares.
- Use of proceeds: working capital, including research, clinical development and commercialization, and support for advancing bempikibart into future clinical trials.
- Underwriters: Morgan Stanley, Jefferies and Cantor (joint book-running managers); Oppenheimer & Co. (book-running manager); H.C. Wainwright & Co. (lead manager).
The company did not provide additional specifics about offering pricing or the precise allocation of net proceeds beyond the broad categories listed above.